Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim's Buy List

Neurocrine Biosciences Inc. (NASDAQ:NBIX) is one of the 11 best debt-free stocks to invest in right now. Following a recent investor meeting with Neurocrine Biosciences’ senior leadership, Guggenheim analyst Yatin Suneja reaffirmed a Buy rating on the stock on June 4, keeping his price target steady at $165. The discussion covered several key areas of interest to investors, including commercial performance and future catalysts.

Management pointed to continued momentum in Ingrezza, with expectations for quarter-over-quarter sales growth in Q2 and a stronger performance in the second half of 2025. They also addressed investor concerns about potential pricing pressure on TEVA’s Austedo under the Inflation Reduction Act. While the IRA remains a point of uncertainty, the management is working toward equal access with TEVA.

The team also highlighted a significant population of untreated patients, underscoring long-term growth potential for VMAT2 inhibitors.

Neurocrine Biosciences Inc. (NASDAQ:NBIX) is a leading neuroscience-focused biopharmaceutical company that discovers and develops treatments for patients with underserved neurological, neuroendocrine, and neuropsychiatric disorders.

While we acknowledge the potential of NBIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and 20 Undervalued Momentum stocks that are Taking Off.

Disclosure: None. This article is originally published at Insider Monkey.